Iain Stuart - 02 Sep 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Chief Scientific Officer
Signature: /s/ Mutya Harsch, attorney-in-fact for Iain Stuart
Issuer symbol: VYNE
Transactions as of: 02 Sep 2021
Net transactions value: $0
Form type: 4
Filing time: 03 Sep 2021, 17:34:41 UTC
Previous filing: 02 Jul 2021
Next filing: 01 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$0	+60,859	+64%	$0.000000	156,609	02 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VYNE	Stock Options	Award	$0	+60,860		$0.000000	60,860	02 Sep 2021	Common Stock	60,860	$1.68	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.
F2	50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.